CALC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CALC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CalciMedica's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.15.
CalciMedica's EPS (Diluted) for the three months ended in Mar. 2024 was $0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.15.
CalciMedica's EPS without NRI for the three months ended in Mar. 2024 was $-0.32. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -2.48.
During the past 3 years, the average EPS without NRI Growth Rate was 51.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 6 years, CalciMedica's highest 3-Year average EPS without NRI Growth Rate was 51.50% per year. The lowest was -74.50% per year. And the median was 15.80% per year.
The historical data trend for CalciMedica's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CalciMedica Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EPS (Basic) | Get a 7-Day Free Trial | -42.68 | -73.50 | -23.66 | -111.16 | -7.66 |
CalciMedica Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EPS (Basic) | Get a 7-Day Free Trial | -23.43 | -1.11 | -0.82 | -0.23 | 0.01 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
CalciMedica's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-34.357 | - | 0) | / | 4.486 | |
= | -7.66 |
CalciMedica's Basic EPS for the quarter that ended in Mar. 2024 is calculated as
Basic EPS (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (0.13 | - | 0) | / | 9.755 | |
= | 0.01 |
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CalciMedica (NAS:CALC) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of CalciMedica's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert N Wilson | director | C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933 |
A. Rachel Leheny | director, 10 percent owner, officer: Chief Executive Officer | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Eric W Roberts | director, 10 percent owner, officer: Chief Business Officer | VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022 |
Sudarshan Hebbar | officer: Chief Medical Officer | C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037 |
Fred A Middleton | director, 10 percent owner | 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708 |
Eric Bjerkholt | director | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Sanderling Ventures Vii (canada), L.p. | 10 percent owner | 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402 |
Sanderling Ventures Management Vi | 10 percent owner | 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402 |
Sanderling Vi Beteiligungs Gmbh & Co Kg | 10 percent owner | 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402 |
Sanderling Vi Limited Partnership | 10 percent owner | 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402 |
Sanderling Venture Partners Vi Co Investment Fund Lp | 10 percent owner | 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402 |
Sanderling Venture Partners Vi Lp | 10 percent owner | 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402 |
Allan Shaw | director | C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018 |
Michael J. Dunn | officer: President and COO | C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037 |
Kenneth A. Stauderman | officer: Chief Scientific Officer | C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037 |
From GuruFocus
By PRNewswire • 09-06-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By Marketwired • 08-09-2023
By PRNewswire • 01-22-2024
By GuruFocus Research • 05-26-2023
By sperokesalga sperokesalga • 05-23-2023
By GuruFocus Research GuruFocus Editor • 05-25-2023
By sperokesalga sperokesalga • 03-20-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By sperokesalga sperokesalga • 06-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.